This inventor holds 1 USPTO granted patent. Top assignee: Schering Aktiengesellschaft. Active years: 2007.
Company Filing History:
Years Active: 2007
Title: Youriy Mitev: Innovator in Estrogen Receptor Ligand Screening
Introduction
Youriy Mitev is a notable inventor based in Jena, Germany. He has made significant contributions to the field of biochemistry, particularly in the area of estrogen receptor research. His innovative methods have the potential to impact the treatment of various neurodegenerative disorders.
Latest Patents
Youriy Mitev holds a patent for a method titled "In Vitro Screening for Ligands of the Estrogen Receptor." This patent describes a comprehensive approach for screening test substances to identify ligands that interact with the estrogen receptor. The method utilizes two assay systems: a cellular or tissue assay system and an enzymatic assay system. The process begins with selecting test substances that exhibit transcriptional ER-mediated activity, measured by an ER-driven reporter gene. The selected substances are then tested in an enzymatic assay to measure their interaction with SRC-1 and the estrogen receptor. The ligands identified through this method are particularly useful for treating and preventing neurodegeneration in the cerebral cortex, including age-related cognitive disorders and Alzheimer's disease.
Career Highlights
Youriy Mitev is associated with Schering Aktiengesellschaft, a company known for its research and development in pharmaceuticals. His work has contributed to advancements in understanding estrogen receptor interactions and their implications for neurodegenerative diseases.
Collaborations
Youriy has collaborated with notable colleagues such as Gernot Langer and Vladimir Patchev. Their combined expertise has furthered research in the field of estrogen receptor ligands.
Conclusion
Youriy Mitev's innovative work in the screening of estrogen receptor ligands represents a significant advancement in biochemistry and medicine. His contributions have the potential to lead to new treatments for serious cognitive disorders.